The great number of biomarkers basic research is presenting in different clinical scenarios of prostate cancer demands the scientific community rigor in their molecular and clinical development for the selection of those which could supply diagnostic and prognostic information for the established nomograms of clinical-pathological factors.
Prostate cancer, due to its prevalence and heterogeneity, needs a more directed diagnosis, characterization of malignant potential and monitoring of its multiple therapies. In this review article we try to go over the recent incorporation of new serum and urine markers in the clinical management of this tumor, emphasizing those with greater clinical development.
Written by:
Rubio-Briones J, Casanova-Casas I, Fernandez-Serra A, Casanova Ramon-Borja J, Ramirez Backhaus M, Collado Sierra A, Dominguez-Escrig J, Gomez-Ferrer A, Lopez-Guerrero JA. Are you the author?
Urology Department and Molecular Biology Laboratory, IVO, Valencia, Spain.
Reference: Arch Esp Urol. 2013 Jun;66(5):440-52.
PubMed Abstract
PMID: 23793762
Article in Spanish.
UroToday.com Prostate Cancer Section
